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Congenital malformations of the inferior vena cava (IVC) are rare and underreported. They can be a risk factor for deep
venous thrombosis (DVT) as a result of inadequate venous drainage of the lower extremities through collateral circulation. The
significant number of cases reported in the literature highlights their importance, warranting investigating their existence in
younger individuals with idiopathic DVT of the lower extremities and pelvic veins. In this systematic review, we depict the typical
presentation of IVC malformations, their management, and the management of their associated DVT.

1. Introduction
The inferior vena cava (IVC) congenital variants include agenesis, interruption with azygous or hemiazygous continuation, web formation, hypoplasia, left-sided location, and
duplication; these conditions may be identified solely or in
conjunction with one another. Their projected prevalence in
the general population is approximately 4% [1]; IVC anomalies are usually asymptomatic and are incidentally diagnosed
during investigations for other medical conditions. Different
theories attempted explaining their unclear etiologies such as
aberrant embryologic development of the posterior cardinal,
subcardinal, supracardinal, and vitelline veins at around
the sixth gestational week [2] or the development of IVC
thrombosis during the intrauterine or perinatal life [3]. The
most reported anatomic anomaly in this case series is IVC
agenesis ranging from 1/100 to 1/200,000 in the general
population [4] and in 5% of deep venous thrombosis (DVT)
patients younger than 30 years [5]. Evidence has shown
that patients with agenesis of inferior vena cava (AIVC) are
prone to develop deep vein thrombosis (DVT) of the lower

extremities at a younger age [6]. This warrants investigating
IVC malformation as an etiologic factor in young patients
diagnosed with idiopathic DVT.
Until recently and due to the rarity of this condition, only
single case reports described DVT in patients with IVC
malformations and thereby its clinical presentation, management, and sequelae remain poorly understood. This paper
attempts to report all cases of DVT in patients with IVC
anomalies in the literature along with a review of symptomatology, diagnosis, and treatment. We aim to raise awareness
of IVC anomalies as a risk factor in young patients with
idiopathic DVT.

2. Methods
We conducted a systematic search on PubMed, Medline,
Ovid, Google Scholar, and Cochrane data search engines
of English language case reports and case series reporting DVT in patients with agenesis, hypoplasia, and any
other malformations of the inferior vena cava. The search
was performed by three authors independently. Eighty-six
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publications have been identified, predominantly case reports
from 1988 to 2015, totaling 188 patients. Four publications
were excluded because of lack of sufficient and relevant data,
given that our goal is addressing several valuable questions
in clinical practice. We focused our statistical analysis on
the demographic data of the patients with IVC anomalies,
clinical DVT presentation, comorbidities, contribution of
thrombophilia screening, and therapeutic management.

3. Results
We identified 188 patients with IVC malformation presenting
with DVT. Patient characteristics are presented in Table 1.
Mean age at diagnosis of DVT was 27.5 ± 11.4 years (min.
9, max. 72) particularly; 138 patients (73.4%) were under 30
years of age. Male to female ratio was 4 : 1.
Patients typically presented with leg swelling, leg pain,
lower back pain, and/or abdominal pain. Only four patients
were asymptomatic, and one patient was admitted for polytrauma with a subsequent diagnosis of DVT.
In the majority of cases, the diagnostic workup of DVT
and IVC anomalies consisted of ultrasonography (US) followed by computed tomography (CT) scanning with intravenous contrast (25%). Other modalities such as magnetic
resonance imaging (MRI) and venography in combination
with US and CT were occasionally performed.
Imaging reported bilateral DVT in 48.9% of the cases and
similar prevalence of right-sided only (25.3%) or left-sided
only (25.8%) DVT (Table 1). All patients were diagnosed with
one of the following IVC anomalies: prerenal IVC agenesis
(13.8%), infrarenal IVC agenesis (17%), postrenal IVC agenesis (0.5%), infrahepatic IVC agenesis (7%), IVC hypoplasia
(4.2%), IVC duplication (2.7%), and IVC agenesis not further
classified (54.8%). In 15 cases, associated anomalies were
also present, largely right kidney aplasia (7 patients) and
left kidney aplasia (5 patients). The others were polysplenia
(2 patients) and right hepatic lobe agenesis (1 patient).
After initial imaging, 168 patients (90%) were screened for
genetic blood coagulation disorders with positive findings in
68 (40.5%). The most prevalent was factor V Leiden mutation
in 19 patients followed by prothrombin G20210A mutation
(8 cases), protein C or protein S deficiency (4 cases), and lupus
anticoagulant (4 cases). The others had one of the following:
antiphospholipid antigens, hyperhomocysteinemia, factor
VIII elevation, and antithrombin III deficiency. Twenty-four
patients were found positive for two or three thrombophilic
factors (Table 2).
Management mostly consisted of anticoagulation with
unfractionated heparin (35.2%) or low molecular weight
heparin (LMWH) (22.1%). DVT management in 35 patients
required one of the following surgical procedures: prosthetic bypass (11.7%), pharmacomechanical catheter-directed
thrombolysis (PCDT) (8.4%), surgical thrombectomy (1.9%),
or IVC Greenfield filter (0.6%) as summarized in Table 3.
Almost all patients (99%) were discharged on vitamin K
antagonists (VKA), mainly warfarin, and/or elastic compression stockings for a period of at least 6 months. Factor Xa
inhibitors (Rivaroxaban and Apixaban) were prescribed in
two cases.
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Table 1: Characteristics of the patients.
Characteristics
Number of patients
Sex: male/female
Age at diagnosis of DVT
Mean (years ± SD)
Range (min.–max.)
DVT site n, (%)∗
Left side
Right side
Bilateral
Type of IVC malformation n, (%)
Infrarenal IVC agenesis
Prerenal IVC agenesis
Postrenal IVC agenesis
Infrahepatic IVC agenesis
IVC hypoplasia
IVC duplication
Nonspecified IVC agenesis

188
142/46
27.5 ± 11.4
9–72
47
46
89

(25.8%)
(25.3%)
(48.9%)

32
26
1
13
8
5
103

(17%)
(13.8%)
(0.5%)
(7%)
(4.2%)
(2.7%)
(54.8%)

DVT, deep vein thrombosis; IVC, inferior vena cava; SD, standard deviation.
∗
Out of 182, 6 cases are not documented.

Table 2: Prevalence of hereditary disorders of coagulation.
Coagulation defect (n, %)
Factor V Leiden
Prothrombin G20210A mutation
Protein S/C deficiency
Lupus anticoagulant
Antiphospholipid antibodies
Hyperhomocysteinemia
Factor VIII elevation
Antithrombin III deficiency
Two thrombophilic factors positive
Three thrombophilic factors positive
Negative thrombophilia test
Not tested

19
8
4
4
3
2
2
2
17
7
100
20

(10.1%)
(4.3%)
(2.1%)
(2.1%)
(1.6%)
(1.1%)
(1.1%)
(1.1%)
(9.1%)
(3.7%)
(53.1%)
(10.6%)

Sixty cases were followed up with imaging studies, mainly
duplex venous ultrasound, for a mean period of 12.9 ± 12.4
months [range: 30 days–5 years]. Recurrence was demonstrated in 23 and resolution in 37 patients.

4. Discussion
A thrombophilic state leading to venous thrombosis can be
inherited or acquired. The most prevalent inherited hypercoagulable states are factor V Leiden mutation, prothrombin
gene mutation, MTHFR gene mutation, lupus anticoagulant,
defects in protein S, protein C, and antithrombin, and dysfibrinogenemia. The most frequently encountered acquired
risk factors are immobility for more than 48 hours in the
past month, surgery, malignancy, infection in the past three
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Table 3: Hospital and long-term treatment of DVT and follow-up.
∗

Hospital management n, (%)
Unfractionated heparin
LMWH
Prosthetic bypass
PCDT
Surgical thrombectomy
IVC-filter
Nonspecified anticoagulation
Long-term treatment n, (%)
Prolonged/lifelong VKA
Prolonged/lifelong VKA +
Compression stockings
6-month VKA
12-month VKA
Follow-up duration in months∗∗
Mean ± SD
Range

54
34
18
13
3
1
31

(35.2%)
(22.1%)
(11.7%)
(8.4%)
(1.9%)
(0.6%)
(20.1%)

135
32

(71.8%)
(17%)

11
8

(5.8%)
(4.4%)
12.85 ± 12.4
1–60

DVT, deep vein thrombosis; IV, intravenous; LMWH, low molecular weight
heparin; PCDT, pharmacomechanical catheter-directed thrombolysis; VKA,
vitamin K antagonist; SD, standard deviation.
∗
Out of 154, 34 cases are not reported.
∗∗
Reported only in 60 cases.

months, current hospitalization, and pregnancy. A number
of drugs have also been associated with an increased risk
of venous thrombosis: oral and transdermal contraceptives,
hormone replacement therapy, glucocorticoids, and others.
Inferior vena cava malformations, especially if concomitantly
present with other thrombophilic conditions, are a potential
risk factor for DVT as they might result in insufficient
venous drainage of the lower extremities through collateral
circulation resulting in blood stasis.
4.1. Incidence. The estimated prevalence of congenital IVC
malformations is difficult to determine but it has been
projected to be approximately 4% in the general population
[1]. They usually remain asymptomatic during childhood
and manifest themselves in the early adulthood, especially
in the presence of other thrombotic risk factors [7]. The
rate of DVT in patients younger than 30 years of age with
IVC malformations is estimated to be 5% versus 0.5–0.6%
in the same group with no IVC anomalies [8]; moreover,
the incidence of bilateral thrombosis in patients with IVC
anomalies ranges from 35.4% to 60% [9, 10].
Literature has demonstrated that 90% of IVC anomalies
involve the suprarenal segment and only 6% involve the
renal or infrarenal segments, making absent infrarenal IVC
the rarest congenital anomaly [11, 12]. In contrast, in our
case series, infrarenal IVC agenesis was the most prevalent
among the IVC anomalies (17%), followed by prerenal and
infrahepatic IVC, and it is important to note that IVC
agenesis was not further classified in 54.8% of the cases.
4.2. Coagulation Profile. Screening for thrombophilia is important when evaluating DVT patients having an IVC

anomaly as it would affect the management approach in terms
of duration of anticoagulation, prevention, and follow-up
strategies. Thrombophilia screening includes the assessment
of factor V Leiden mutation, prothrombin G20210A mutation, antiphospholipid antibodies, methylenetetrahydrofolate
reductase gene mutation, lupus anticoagulant, antithrombin,
and proteins C and S activities [13]. Rogers et al. reported
that 44% of patients with absent IVC also had a positive
thrombophilia screening [14]. We report a similar incidence
rate in this series (40.5%) suggesting a complementary causal
relation between IVC anomalies and thrombophilia on the
one hand and pathogenesis of DVT on the other hand.
4.3. Symptoms. Low-back and abdominal pain have been
reported as the most common initial presenting symptoms
[15], favoring the hypothesis that the thrombotic process
initially involves the IVC and only afterwards descends to
the pelvic and lower extremities veins. In our series, back
and abdominal pain, with an incidence of 17% and 12.8%,
respectively, always manifested themselves together with
DVT symptoms such as lower extremity pain and edema.
4.4. Diagnosis. Ultrasonography of the lower extremities is
the first imaging test to be performed when DVT is suspected.
The IVC is not typically investigated for anatomic anomalies
by US as its accuracy is limited for being operator-dependent
and secondary to interference of bowel gas and body habitus
in overweight and obese patients [1]. In this case series,
83% of patients underwent US as the first imaging modality
but the most common diagnostic tool was CT scan with
intravenous contrast (86%). Abdominal CT scan with IV
contrast shows enhancement in the renal and suprarenal
IVC but may also show admixture artifacts in the infrarenal
portion of the IVC; however, delaying the scan from 60–
70 to 70–90 seconds after contrast administration allows a
more uniform enhancement of the entire IVC [16]. Despite
its advantage of being a rapid noninvasive imaging modality,
MRI imaging is now replacing CT as the optimal investigative
tool avoiding radiation and giving more accurate delineation
of thrombus as well as any IVC anomaly. MRI is also used
to follow up patients to determine morphological changes in
the thrombus following therapy [17]. Only 56% of patients in
our case series underwent MRI; however, in the case reports
from 2014 onwards, 79% underwent an MRI underlining the
tendency mentioned above. Moreover, venography and other
invasive diagnostic tools are being replaced by US, CT, and
MRI.
4.5. Management, Sequelae, and Follow-Up. Controversy exists regarding the evidence-based management approach of
DVT associated with IVC abnormalities. Given the rarity of
this condition, performing clinical trials to determine the
best treatment strategy is prohibitive. From this case series,
the largest on the topic, we try to derive a trend in both the
inpatient acute setting and the outpatient management.
As the diagnosis of DVT associated with IVC anomalies
is confirmed, patients are treated either conservatively with
unfractionated heparin and LMWH (35.2% and 22.1% in our
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case series) or surgically for severe venous insufficiency not
correctable with anticoagulation alone manifested by nonhealing lower extremity ulcers. Surgical options were prosthetic bypass (11.7%), pharmacomechanical catheter-directed
thrombolysis (PCDT) (8.4%), surgical thrombectomy (1.9%),
or IVC Greenfield filter (0.6%). PCDT, compared to systemic
anticoagulation alone, significantly decreases the thrombus
burden and incidence of recurrent DVT in patients with
extensive iliofemoral DVT [18]. PCDT could be a treatment
option in patients with symptomatic iliofemoral DVT, good
functional status, life expectancy of 1 year or more, and low
risk of bleeding [19]. However, studies focusing on the longterm outcomes following PPCDT are desperately needed as
evidence is lacking.
In the outpatient setting, adjustment of modifiable risk
factors (i.e., oral contraceptive pills, immobilization, and
major physical activity), compression stockings, and longterm anticoagulation are the treatment of choice. In this case
series, patients were prescribed oral vitamin K antagonists,
mostly warfarin, with a target international normalized ratio
(INR) range of 2-3. Factor Xa inhibitors (Rivaroxaban and
Apixaban) were prescribed in two cases. 17% of patients were
prescribed compression stockings. There is no consensus
concerning the duration of anticoagulation. In this case
series, 11 patients discontinued oral anticoagulation therapy
at 6 months and 8 patients at 1 year. All others were on
long-term anticoagulation that was decided on case-bycase basis according to treating physicians with or without
compression stockings. At least 3 to 6 months of anticoagulation is required for DVT associated with IVC agenesis.
While the majority of patients might have other risk factors,
prolonged oral anticoagulation and compression stockings
are recommended [20]. Follow-up, mainly by US, aims at
detecting DVT recurrence. Currently, no data exists on longterm morbidity and mortality following DVT associated with
IVC abnormalities.

5. Conclusion
A high index of suspicion for inferior vena cava anomalies
should be considered in young patients presenting with deep
vein thrombosis. We suggest being liberal in screening for
IVC anomalies in this high risk group.
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